Xiaobin Wu sold $12M of ONC
President, COO & GM China at BeiGene, Ltd.. 51,921 shares at an average of $240.46, traded Feb 18, 2025, filed Feb 20, 2025.
Score components
- +20RolePresident
- +25Trade size$12.5M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001651308-25-000018, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 18, 2025 | MOption exercise American Depositary Shares10b5-1 | +30,654 | $169.65 | $5.2M | 30,654 | Feb 20, 2025 |
| Feb 18, 2025 | SOpen-market sale American Depositary Shares10b5-1 | -19,576 | $240.31 | $4.7M | 11,078 | Feb 20, 2025 |
| Feb 18, 2025 | SOpen-market sale American Depositary Shares10b5-1 | -7,919 | $241.26 | $1.9M | 3,159 | Feb 20, 2025 |
| Feb 18, 2025 | SOpen-market sale American Depositary Shares10b5-1 | -3,159 | $242.08 | $765k | 0 | Feb 20, 2025 |
| Feb 20, 2025 | MOption exercise American Depositary Shares10b5-1 | +21,267 | $169.65 | $3.6M | 21,267 | Feb 20, 2025 |
| Feb 20, 2025 | SOpen-market sale American Depositary Shares10b5-1 | -21,267 | $240.07 | $5.1M | 0 | Feb 20, 2025 |
| Feb 18, 2025 | MOption exercise Share Option (Right to Buy)derivative10b5-1 | -398,502 | $0.00 | $0 | 368,097 | Feb 20, 2025 |
| Feb 20, 2025 | MOption exercise Share Option (Right to Buy)derivative10b5-1 | -276,471 | $0.00 | $0 | 91,626 | Feb 20, 2025 |
Related signals
Other insiders at BeiGene, Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | BeiGene, Ltd. | Chan Henry Lee SVP, General Counsel | $418k 1,115 shares | -100% | |
| 33Weak | BeiGene, Ltd. | Xiaodong Wang director, other | $11M 31,028 shares | -100% | |
| 33Weak | BeiGene, Ltd. | Xiaodong Wang director, other | $13M 38,287 shares | -527% | |
| 49Moderate | BeiGene, Ltd. | Titus B. Ball Principal Accounting Officer | $47k 132 shares | -100% | |
| 83Strong | BeiGene, Ltd. | John Oyler Chief Executive Officer | $830k 3,174 shares | -100% | |
| 48Moderate | BeiGene, Ltd. | Xiaodong Wang director, other | $533k 2,007 shares | -100% | |
| 70Notable | BeiGene, Ltd. | Xiaobin Wu President and COO | $354k 1,363 shares | -100% | |
| 63Notable | BeiGene, Ltd. | Lai Wang Global Head of R&D | $267k 1,028 shares | -100% | |
| 85Strong | BeiGene, Ltd. | John Oyler Chief Executive Officer | $1.4M 5,140 shares | -100% | |
| 74Notable | BeiGene, Ltd. | Xiaobin Wu President and COO | $568k 2,173 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.